|
|
 Previous Article | Table of Contents | Next Article 
Distinctive immunophenotypic features of t(8;21)(q22;q22) acute
myeloblastic leukemia in children [see comments]
CA Hurwitz, SC Raimondi, D Head, R Krance, J Mirro , DK Kalwinsky, GD Ayers and FG Behm
Department of Pathology, St Jude Children's Research Hospital, Memphis, TN
38101-0318.
Thirty cases of newly diagnosed pediatric acute myeloblastic leukemia (AML)
with French-American-British (FAB) M2 morphology were analyzed with
cytogenetics and a comprehensive panel of monoclonal antibodies reactive
with lymphoid-, natural killer (NK)-cell-, and myeloid- associated
antigens. The t(8;21)(q22;q22), or t(8;21;V)(q22;q22;V), translocation was
identified in 16 of the 30 cases. Cases with the t(8;21) did not differ
significantly from the remaining M2 cases with respect to expression of
CD11b, CD13, CD14, CD15, CD33, CD34, CD36, CD41a, CD42b, CDw65, TdT, or
HLA-DR. Expression of the B-cell antigen CD19 was detected in 13 of the 16
t(8;21) cases (81%), but in only 1 of the 14 (7%) other M2 cases (P =
.00006). Expression of the CD56 NK-cell antigen was also significantly more
frequent among t(8;21) cases (63% v 14%; P = .01). Coexpression of CD19 and
CD56 was found only in the t(8;21) group (9 of 16 cases, P = .0009).
Furthermore, this phenotype was not found in 48 evaluable cases of de novo
AML of the FAB M1, M3, M4, M5, or M7 subtypes. The 14 M2 AML cases lacking
the t(8;21) commonly expressed CD2 (n = 5) or CD7 (n = 8). However, no case
with the t(8;21) expressed either antigen (P = .01 and .0005,
respectively). Thus, the t(8;21) biologic subgroup of pediatric M2 AML has
distinct immunophenotypic characteristics that distinguish it from other
types of de novo AML.
Volume 80,
Issue 12,
pp. 3182-3188,
12/15/1992
Copyright © 1992 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
M. E. Ross, R. Mahfouz, M. Onciu, H.-C. Liu, X. Zhou, G. Song, S. A. Shurtleff, S. Pounds, C. Cheng, J. Ma, et al.
Gene expression profiling of pediatric acute myelogenous leukemia
Blood,
December 1, 2004;
104(12):
3679 - 3687.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Saussoy, J.-L. Vaerman, N. Straetmans, V. Deneys, G. Cornu, A. Ferrant, and D. Latinne
Differentiation of Acute Myeloid Leukemia from B- and T-Lineage Acute Lymphoid Leukemias by Real-Time Quantitative Reverse Transcription-PCR of Lineage Marker mRNAs
Clin. Chem.,
July 1, 2004;
50(7):
1165 - 1173.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Orfao, G. Schmitz, B. Brando, A. Ruiz-Arguelles, G. Basso, R. Braylan, G. Rothe, F. Lacombe, F. Lanza, S. Papa, et al.
Clinically Useful Information Provided by the Flow Cytometric Immunophenotyping of Hematological Malignancies: Current Status and Future Directions
Clin. Chem.,
October 1, 1999;
45(10):
1708 - 1717.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. K. Murray, E. Estey, E. Paietta, R. S. Howard, W. J. Edenfield, S. Pierce, K. P. Mann, C. Bolan, and J. C. Byrd
CD56 Expression in Acute Promyelocytic Leukemia: A Possible Indicator of Poor Treatment Outcome?
J. Clin. Oncol.,
January 1, 1999;
17(1):
293 - 293.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. D. Jennings and K. A. Foon
Recent Advances in Flow Cytometry: Application to the Diagnosis of Hematologic Malignancy
Blood,
October 15, 1997;
90(8):
2863 - 2892.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. R. Baer, C. C. Stewart, D. Lawrence, D. C. Arthur, J. C. Byrd, F. R. Davey, C. A. Schiffer, and C. D. Bloomfield
Expression of the Neural Cell Adhesion Molecule CD56 Is Associated With Short Remission Duration and Survival in Acute Myeloid Leukemia With t(8; 21)(q22; q22)
Blood,
August 15, 1997;
90(4):
1643 - 1648.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Rothe, H. Gabriel, E. Kovacs, J. Klucken, J. Stohr, W. Kindermann, and G. Schmitz
Peripheral Blood Mononuclear Phagocyte Subpopulations as Cellular Markers in Hypercholesterolemia
Arterioscler. Thromb. Vasc. Biol.,
December 1, 1996;
16(12):
1437 - 1447.
[Abstract]
[Full Text]
|
|
|
|
|
